Biopharmx Corp (BPMX) Expected to Post Earnings of -$0.06 Per Share

Equities analysts expect Biopharmx Corp (NYSE:BPMX) to announce earnings per share (EPS) of ($0.06) for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Biopharmx Corp’s earnings, with the highest EPS estimate coming in at ($0.04) and the lowest estimate coming in at ($0.07). Biopharmx Corp posted earnings per share of ($0.12) in the same quarter last year, which suggests a positive year over year growth rate of 50%. The firm is expected to issue its next earnings report on Tuesday, December 12th.

According to Zacks, analysts expect that Biopharmx Corp will report full-year earnings of ($0.24) per share for the current fiscal year, with EPS estimates ranging from ($0.28) to ($0.20). For the next year, analysts expect that the business will report earnings of ($0.20) per share, with EPS estimates ranging from ($0.25) to ($0.15). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that that provide coverage for Biopharmx Corp.

TRADEMARK VIOLATION WARNING: This report was published by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this report on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The correct version of this report can be viewed at https://stocknewstimes.com/2017/11/11/biopharmx-corp-bpmx-expected-to-post-earnings-of-0-06-per-share-2.html.

Biopharmx Corp Company Profile

BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.

Get a free copy of the Zacks research report on Biopharmx Corp (BPMX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Biopharmx Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx Corp and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply